PRESS RELEASE published on 05/30/2023 at 07:30, 1 year 5 months ago Formycon reports results for the first quarter 2023
PRESS RELEASE published on 05/10/2023 at 07:30, 1 year 6 months ago Formycon Announces Participation in International Investor Conferences in Q2/2023
PRESS RELEASE published on 04/27/2023 at 07:30, 1 year 6 months ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 1 year 6 months ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 1 year 9 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 1 year 9 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 1 year 9 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 1 year 9 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 1 year 9 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
PRESS RELEASE published on 02/01/2023 at 17:40, 1 year 9 months ago EQS-Adhoc: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Published on 11/21/2024 at 17:35, 1 hour 19 minutes ago 1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 1 hour 24 minutes ago SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 2 hours 24 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 53 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 54 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 18:36, 18 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:51, 1 hour 2 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 1 hour 3 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 11 hours 56 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 23 hours 34 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 1 hour ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 1 hour ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 11 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
